This trial is active, not recruiting.

Conditions myeloma, multiple, paraproteinemias, hematologic neoplasms
Sponsor Ohio State University Comprehensive Cancer Center
Start date April 2014
End date June 2017
Trial size 111 participants
Trial identifier NCT02033928, OSU-13135


The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Primary Outcomes

Change in Comprehensive Frailty Assessment
time frame: up to 14 months

Secondary Outcomes

Time to progression
time frame: date of enrollment to date of documented clinical progression up to two years post-enrollment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - patients with a plasma cell dyscrasia AND/OR any patient receiving a stem cell transplant for a hematologic malignancy at The Ohio State University - at least 18 years of age Exclusion Criteria: - Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.

Additional Information

Official title Comprehensive Frailty Assessment
Principal investigator Ashley Rosko, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center.